Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,630.09
(
0.08%
)
US TECH 100
23,617.80
(
-0.75%
)
Dow Jones
46,217.69
(
-0.02%
)
Brent Oil
101.71
(
-4.57%
)
Bitcoin
70,488.12
(
-1.06%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 164769

Wednesday, 07/31/2013 4:26:47 PM

Wednesday, July 31, 2013 4:26:47 PM

Post# of 257259
ENTA is a screaming buy based on valuation, IMO. ABT-450 is a so-so drug, but the economics of ENTA’s partnership with ABBV (#msg-89280314) almost assure that the share price will rise unless a safety problem derails ABBV’s HCV program (#msg-90408583, #msg-90352754). On top of that, you get the NVS partnership for free.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now